FDA position on Cholestin violates "letter and spirit" of DSHEA, Pharmanex says.
This article was originally published in The Tan Sheet
Executive Summary
FDA POSITION ON CHOLESTIN VIOLATES "LETTER AND SPIRIT" OF DSHEA, Pharmanex maintains in a statement outlining its "preliminary" reaction to FDA's Sept. 30 letter on the product marketed as a dietary supplement. FDA's position "ignores the facts placed before the agency and appears designed to protect the market for pharmaceuticals approved for the treatment of cholesterol-related conditions -- without regard to Congress's framework for the regulation of dietary supplements" in the Dietary Supplement Health & Education Act, Pharmanex states. The company has not sent FDA a formal response.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning